Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Fujita, Yusei ^a   Kato, Itsuro ^a   Iwai, Soichi ^a   Ono, Koji ^b   Suzuki, Minoru ^b   Sakurai, Yoshinori ^b   Ohnishi, Ken ^c   Ohnishi, Takeo ^c   Yura, Yoshiaki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 BORONOPHENYLALANINE; CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MUTANT; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; JAPAN; MODULATION; MOUTH CARCINOMA; NEUTRON CAPTURE THERAPY; NEUTRON THERAPY; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WILD TYPE; CELL SEPARATION; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; MOUTH TUMOR; MUTATION; RADIATION EXPOSURE; TUMOR CELL LINE;

APOPTOSIS; BORON NEUTRON CAPTURE THERAPY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MOUTH NEOPLASMS; MUTATION; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74049155490     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-63     Document Type: Article

References (46)

1. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C. Neck disease and distant metastases. Oral Oncol 2003, 39:207-212. 10.1016/S1368-8375(02)00049-0, 12618192.
2. Palme CE, Gullane PJ, Gilbert RW. Current treatment options in squamous cell carcinoma of the oral cavity. Surg Oncol Clin N Am 2004, 13:47-70. 10.1016/S1055-3207(03)00123-6, 15062361.
3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
4. Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res 2001, 61:88-96.
5. Yamazaki Y, Chiba I, Hirai A, Notani K, Kashiwazaki H, Tei K, Totsuka Y, Iizuka T, Kohgo T, Fukuda H. Radioresistance in oral squamous cell carcinoma with p53 DNA contact mutation. Am J Clin Oncol 2003, 26:e124-129. 10.1097/01.coc.0000091352.60347.f8, 14528086.
6. Niemantsverdriet M, Jongmans W, Backendorf C. Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes. xp Cell Res 2005, 310:E237-247.
7. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res 1999, 151:1-18. 10.2307/3579742, 9973079.
8. Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: Current status and future prospects. Clin Cancer Res 2005, 11:3987-4002. 10.1158/1078-0432.CCR-05-0035, 15930333.
9. Fukuda H, Hiratsuka J, Kobayashi T, Sakurai Y, Yoshino K, Karashima H, Turu K, Araki K, Mishima Y, Ichihashi M. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med 2003, 26:97-103.
10. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004, 2061:1069-1073.
11. Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Mäkitie A, Seppänen M, Minn H, Kotiluoto P, Auterinen I, Savolainen S, Kouri M, Joensuu H. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:475-482.
12. Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, Kumada H, Suzuki M, Maruhashi A, Kirihata M, Ono K. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 2009, 91:199-206. 10.1007/s11060-008-9699-x, 18813875.
13. Iwadate Y, Mizoe J, Osaka Y, Yamaura A, Tsujii H. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53. Int J Radiat Oncol Biol Phys 2001, 50:803-808.
14. Matsui Y, Asano T, Kenmochi T, Iwakawa M, Imai T, Ochiai T. Effects of carbon-ion beams on human pancreatic cancer cell lines that differ in genetic status. Am J Clin Oncol 2004, 27:24-28. 10.1097/01.coc.0000046037.75545.AD, 14758129.
15. Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A, Ando K. Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. J Radiat Res (Tokyo) 2007, 48:317-325. 10.1269/jrr.06081, 17548940.
16. Gong L, Jin X, Li Q, Liu J, An L. Heavy ion beams induce survivin expression in human hepatoma SMMC-7721 cells more effectively than X-rays. Acta Biochim Biophys Sin (Shanghai) 2007, 39:575-582. 10.1111/j.1745-7270.2007.00314.x, 17687492.
17. Takahashi A, Matsumoto H, Yuki K, Yasumoto J, Kajiwara A, Aoki M, Furusawa Y, Ohnishi K, Ohnishi T. High-LET radiation enhanced apoptosis but not necrosis regardless of p53 status. Int J Radiat Oncol Biol Phys 2004, 60:591-597. 10.1016/j.ijrobp.2004.05.062, 15380596.
18. Yamakawa N, Takahashi A, Mori E, Imai Y, Furusawa Y, Ohnishi K, Kirita T, Ohnishi T. High LET radiation enhances apoptosis in mutated p53 cancer cells through Caspase-9 activation. Cancer Sci 2008, 99:1455-1460. 10.1111/j.1349-7006.2008.00818.x, 18422753.
19. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997, 25:151-157. 146396, 9016527, 10.1093/nar/25.1.151.
20. Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003, 63:1188-1191.
21. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H, Ohnishi T, Hosoi H. Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000, 47:495-501. 10.1016/S0360-3016(00)00437-5, 10802378.
22. Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB. Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int J Radiat Oncol Biol Phys 1994, 30:643-652.
23. Obayashi S, Kato I, Ono K, Masunaga S, Suzuki M, Nagata K, Sakurai Y, Yura Y. Delivery of 10boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy. Oral Oncol 2004, 40:474-482. 10.1016/j.oraloncology.2003.09.018, 15006618.
24. Kamida A, Fujita Y, Kato I, Iwai S, Ono K, Suzuki M, Sakurai Y, Yura Y. Effect of neutron capture therapy on the cell cycle of human squamous cell carcinoma cells. Int J Radiat Biol 2008, 84:191-199. 10.1080/09553000801902125, 18300019.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
26. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994, 54:3718-3722.
27. Gallo O, Chiarelli I, Bianchi S, Calzolari A, Simonetti L, Porfirio B. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin Cancer Res 1996, 2:1577-1582.
28. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no?. Cancer Metastasis Rev 2004, 23:237-257. 10.1023/B:CANC.0000031764.81141.e4, 15197326.
29. Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G, Awada A. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006, 28:256-269. 10.1002/hed.20326, 16284973.
30. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908. 10.1038/sj.onc.1208615, 15838523.
31. Masunaga S, Ono K, Takahashi A, Sakurai Y, Ohnishi K, Kobayashi T, Kinashi Y, Takagaki M, Ohnishi T. Impact of the p53 status of the tumor cells on the effect of reactor neutron beam irradiation, with emphasis on the response of intratumor quiescent cells. Jpn J of Cancer Res 2002, 93:1366-1377.
32. Aromando RF, Heber EM, Trivillin VA, Nigg DW, Schwint AE, Itoiz ME. Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model. J Oral Pathol Med 2009, 38:448-454.
33. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004, 4:592-603. 10.1038/nrc1412, 15286739.
34. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816. 10.1016/0092-8674(93)90499-G, 8242751.
35. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:p701-704.
36. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825. 10.1016/0092-8674(93)90500-P, 8242752.
37. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993, 12:53-63. 413175, 8428594.
38. Solomon MJ, Harper JW, Shuttleworth J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40 MO15. EMBO J 1993, 12:3133-3142. 413579, 8344252.
39. Leach SD, Scatena CD, Keefer CJ, Goodman HA, Song SY, Yang L, Pietenpol JA. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res 1998, 58:3231-3236.
40. Russell P, Nurse P. Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 1987, 49:559-567. 10.1016/0092-8674(87)90458-2, 3032459.
41. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 1991, 64:1111-1122. 10.1016/0092-8674(91)90266-2, 1706223.
42. Matsumura S, Matsumura T, Ozeki S, Fukushima S, Yamazaki H, Inoue T, Inoue T, Furusawa Y, Eguchi-Kasai K. Comparative analysis of G2 arrest after irradiation with 75 keV carbon-ion beams and 137Cs γ-rays in a human lymphoblastoid cell line. Cancer Detect Prev 2003, 27:222-228. 10.1016/S0361-090X(03)00063-1, 12787730.
43. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996, 2:1665-1671.
44. Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phy 1999, 43:607-616.
45. Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, Zhao H. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral Maxillofac Surg 2009, 67:1074-1082. 10.1016/j.joms.2008.06.079, 19375021.
46. Tian G, Liu J, Sui J. A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. Anticancer Drugs 2009, 20:403-407. 10.1097/CAD.0b013e328323d6b8, 19318914.